Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Duration of androgen suppression in the treatment of prostate cancer.
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Bolla M, et al. Among authors: van den bergh ac, van tienhoven g, van der steen banasik em. N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095. N Engl J Med. 2009. PMID: 19516032 Free article. Clinical Trial.
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).
Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Bolla M, et al. Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016/S0140-6736(12)61253-7. Epub 2012 Oct 19. Lancet. 2012. PMID: 23084481 Clinical Trial.
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L. Bolla M, et al. Among authors: van den bergh ac, van der steen banasik em. J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976418 Clinical Trial.
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
Bolla M, Neven A, Maingon P, Carrie C, Boladeras A, Andreopoulos D, Engelen A, Sundar S, van der Steen-Banasik EM, Armstrong J, Peignaux-Casasnovas K, Boustani J, Herrera FG, Pieters BR, Slot A, Bahl A, Scrase CD, Azria D, Jansa J, O'Sullivan JM, Van Den Bergh ACM, Collette L; EORTC Radiation Oncology Group. Bolla M, et al. Among authors: van den bergh acm. J Clin Oncol. 2021 Sep 20;39(27):3022-3033. doi: 10.1200/JCO.21.00855. Epub 2021 Jul 26. J Clin Oncol. 2021. PMID: 34310202
Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.
Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik EM, Gulyban A, Collette L, Bolla M; EORTC Radiation Oncology Group. Matzinger O, et al. Eur J Cancer. 2009 Nov;45(16):2825-34. doi: 10.1016/j.ejca.2009.07.009. Epub 2009 Aug 12. Eur J Cancer. 2009. PMID: 19682889 Clinical Trial.
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR. Westgeest HM, et al. Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13. Eur Urol Focus. 2018. PMID: 28753794 Clinical Trial.
Risk of diabetes after para-aortic radiation for testicular cancer.
Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M. Groot HJ, et al. Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9. Br J Cancer. 2018. PMID: 30297773 Free PMC article.
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.
van den Bergh GPA, Kuppen MCP, Westgeest HM, Mehra N, Gerritsen WR, Aben KKH, van Oort IM, van Moorselaar RJA, Somford DM, van den Eertwegh AJM, Bergman AM, van den Bergh ACM, Uyl-de Groot CA. van den Bergh GPA, et al. Among authors: van den bergh acm. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):162-169. doi: 10.1038/s41391-022-00605-7. Epub 2022 Oct 12. Prostate Cancer Prostatic Dis. 2023. PMID: 36224377 Clinical Trial.
61 results